In short
Clinical trials are investigating YL201 in people with advanced solid tumors. These studies are looking at safety, dose limits, and early signs of anti-tumor activity when YL201 is given with atezolizumab. The trial is in Phase 1 and is enrolling adults with advanced solid tumors.
Key points
- Clinical trials are studying YL201 in people with advanced solid tumors. The main trial is a Phase 1 study of YL201 given with atezolizumab. Researchers want to learn about safety, the maximum tolerated dose, and early anti-tumor activity. They are also measuring adverse events, lab changes, dose-limiting toxicities, objective response rate, and progression-free survival. The study plans to enroll 243 participants and is currently authorised.
Trial overview
The available trial data describe one interventional study of YL201 in people with advanced solid tumors. An interventional study means the researchers give a treatment and then measure what happens.
This study is listed as Authorised and is in Phase 1. The planned enrollment is 243 participants.
Who the study is for
The trial is designed for patients with advanced solid tumors. The source data does not give more detailed eligibility rules, so we cannot say which exact cancer types or patient features are needed.
The study title says YL201 is being tested in combination with other anti-cancer therapies, and the brief summary names atezolizumab as the partner treatment.
What researchers are measuring
In Part 1, the main goals are to assess safety and to find the maximum tolerated dose (MTD) of YL201 when used with atezolizumab. Safety means watching closely for problems during treatment.
The primary endpoints in Part 1 include adverse events (medical problems that happen during the study), laboratory abnormalities (unusual blood or lab test results), and dose-limiting toxicities (serious side effects that limit dosing).
In Part 2, the trial looks at anti-tumor activity, which means whether the treatment shows signs of helping the cancer. The primary endpoints in Part 2 are objective response rate (ORR) and progression-free survival (PFS), both assessed using RECIST version 1.1.
Study design and phase
This is a Phase 1 study, which is usually the first step in testing a treatment combination in people. Phase 1 studies often focus on safety, dose finding, and early signs that the treatment may work.
The study is not a simple single-purpose trial. It has two parts: Part 1 focuses on safety and dose finding, and Part 2 focuses on whether the treatment has anti-cancer activity.
What the combination study is trying to learn
The brief summary says Part 1 is meant to assess the safety of YL201 in combination with atezolizumab and to determine the MTD. This helps researchers understand how the combination behaves in the body in a study setting.
Part 2 is meant to assess the anti-tumor activity of the same combination. The study uses scan-based measures such as ORR and PFS to see whether tumors shrink and how long the cancer stays controlled.
Because the source data only includes one authorised trial, the current picture of YL201 research is limited to this advanced solid tumor study.
Key patient terms
Objective response rate means the share of patients whose tumors get smaller or disappear on scans.
Progression-free survival means the length of time before the cancer gets worse.
RECIST version 1.1 is a standard system doctors and researchers use to measure tumor changes on imaging scans.
Dose-limiting toxicities are side effects that are serious enough to stop researchers from giving more of the treatment.